🔍

IOL Chemicals and Pharmaceuticals Limited (IOLCP)

₹194.69 -0.20% last close, 16 Oct

📊 NSE: IOLCP 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📢 Latest filing: 25 Sep 2026 📝 Analysis written: 14 Dec 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, IOL Chemicals' revenue was ₹756 Cr (+37.1% year on year, +22.2% on the previous quarter), and net profit ₹64.4 Cr (+89.8% year on year); the operating margin was 13.7%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹756	+37.1%	+22.2%
Operating profit	₹103	+66.5%	+12.5%
Net profit	₹64.4	+89.8%	+21.5%
EPS (₹)	2.19	+88.8%	+21.0%
Operating margin	13.7%	—	—

Full quarterly financials → Results calendar →

IOLCP delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 29.33% of the IOLCP shares traded on NSE were taken to delivery, against the stock's own 20-session average of 32.14%. That is close to its usual level. Volume was 0.5 times its average, well below normal.

29.33%Delivery, 16 Oct

32.14%Own 20-session average

0.5×Volume vs its average

₹194.69NSE close · -0.20%

Delivery in the last 5 sessions: 38.2% · 30.1% · 27.6% · 43.6% · 29.3%

Delivery across the market →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

IOLCP Receives EDQM Approval for Fenofibrate Process II Effective Sept 24, 2026

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 25 Sep 2026, 01:31 PM

IOL Chemicals and Pharmaceuticals Limited announced that the European Directorate for the Quality of Medicines & HealthCare (EDQM) granted a Certificate of Suitability (CEP) for 'FENOFIBRATE – Process II' on September 24, 2026. This approval comes in addition to an existing valid CEP already held for Fenofibrate. Process II was developed to meet specific customer requirements in regulated markets, supporting the company's export diversification strategy beyond Ibuprofen and Ethyl Acetate (which comprised 72% of FY24 sales). While no financial terms or capacity additions were quantified, the approval bolsters IOLCP's portfolio of 18+ approved CEPs targeting European and US markets.

Received Certificate of Suitability (CEP) from EDQM on 24th September 2026
Approval granted for API product 'FENOFIBRATE – Process II'
Complements existing valid CEP already held by IOLCP for Fenofibrate
Process II specifically developed to address customized client manufacturing requirements in regulated markets

💡 Track export revenue contribution and commentary in upcoming quarterly results regarding the commercial rollout and client uptake of Fenofibrate Process II.

IOL Chemicals Secures EU-REACH Registration for Triacetin to Expand European Exports

🟢 POSITIVE ⭐ 5/10

REGULATORY 📅 23 Sep 2026, 04:10 PM

IOL Chemicals and Pharmaceuticals Limited announced that it has received REACH certification and registration for its product Triacetin under the EU-REACH framework from the European Chemicals Agency (ECHA). This regulatory approval permits the company to export Triacetin across all European Union member states. The approval aligns with IOLCP's broader strategy to expand in regulated export markets to achieve higher-margin sales. Financial contribution details and target volumes for Triacetin were not disclosed in the filing.

Received REACH certification/registration for product 'Triacetin' under the EU-REACH framework
Approval granted by the European Chemicals Agency (ECHA) announced on 23rd September 2026
Enables export of Triacetin across all European Union member countries
Specific financial contribution, capacity allocation, or sales targets were not disclosed

💡 Track subsequent quarterly commentary to assess commercial export volumes of Triacetin to Europe and its contribution to IOLCP's non-Ibuprofen chemical sales.

IOL Chemicals Dispatches KYC Update Reminders to Physical Shareholders

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 21 Sep 2026, 05:20 PM

IOL Chemicals and Pharmaceuticals Limited informed the exchanges that it completed the dispatch of reminder letters on September 19, 2026, to identified shareholders holding physical shares to update their KYC details. This step is in compliance with SEBI master circulars mandating the linking of PAN, contact details, bank details, and specimen signatures for physical folios. Non-compliant folios will be restricted from processing grievances, service requests, and non-electronic payments. The filing is purely administrative with zero impact on the company's financial or operational performance.

Reminder letters dispatched to physical shareholders on September 19, 2026
Mandated under SEBI Circulars dated February 6, 2026, and June 10, 2024
Requires submission of Form ISR-1, ISR-2, and nomination details to RTA Alankit Assignments
Physical share transfers remain disallowed since April 1, 2019

💡 Physical shareholders must submit Form ISR-1 and related KYC documents to avoid dividend disbursement delays; no action is required for demat equity investors.

IOLCP Details ₹500 Cr Capex Plan to Boost Ibuprofen Capacity and Enter CDMO Formulations

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 17 Sep 2026, 05:13 PM

IOL Chemicals and Pharmaceuticals Limited (IOLCP) conducted an investor call detailing three growth initiatives requiring ~₹500 crore in capex (~20% of TTM revenue). The plan includes expanding Ibuprofen API capacity by 6,000 MTPA to 18,000 MTPA by December 2027 and setting up an EU GMP-certified CDMO formulation facility with a 1,500 million tablets/year capacity starting commercialization in Q3 FY27. Management also disclosed a dedicated tolling facility for specialty chemicals under a long-term customer agreement. Combined, these initiatives are expected to generate an incremental 25% to 30% top-line growth and will be funded entirely through internal accruals, with ~30% already incurred.

Proposed total capex of ~₹500 crore funded entirely via internal accruals, with ~30% already incurred
Expanding Ibuprofen capacity by 6,000 MTPA to 18,000 MTPA, scheduled for commissioning by December 2027
New CDMO facility with capacity of ~1,500 million tablets per annum (EU GMP certified), starting Q3 FY27
Projects expected to contribute an incremental 25% to 30% to total top-line over coming years
Capex projects target asset turns of 1.75x to 2.0x for pharma API investments

💡 Track the commercialization ramp-up of the CDMO formulation plant starting Q3 FY27 and monitor ongoing milestone spending towards the December 2027 Ibuprofen commissioning.

IOL Chemicals Releases Audio Recording of Business Update Call Held on Sep 11, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 11 Sep 2026, 05:52 PM

IOL Chemicals and Pharmaceuticals Limited has informed the exchanges about the availability of the audio recording for its Business Update Conference Call held on September 11, 2026. The call was conducted with analysts and investors pursuant to SEBI Listing Regulations. The audio file has been hosted publicly on the company's website. No specific financial figures, forecasts, or operational updates were detailed in this statutory disclosure document itself.

Audio recording made available for the investor call conducted on September 11, 2026
Call conducted pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015
Audio recording accessible via web link at https://www.iolcp.com/uploads/11092026.mp3
No quantitative metrics or corporate actions disclosed in the regulatory filing

💡 Investors should review the audio recording or await the written transcript to assess any management guidance on Paracetamol capacity utilization and regulated market expansion.

IOL Chemicals Schedules Urgent Business Update Call for Sept 11, 2026

🔵 WATCH ⭐ 4/10

ROUTINE 📅 10 Sep 2026, 03:20 PM

IOL Chemicals and Pharmaceuticals Limited has scheduled a virtual business update conference call with investors and analysts on Friday, September 11, 2026, at 3:00 PM IST. The company stated that the meeting is being called on short notice due to the urgent nature of the business update, dispensing with the standard two working days' advance notice under SEBI regulations. The call will feature key executives including the CFO, Company Secretary, Director of Works, and Finance Advisor & Strategic Head. Specific operational or financial details regarding the business development were not disclosed in the filing.

Conference call scheduled for Friday, 11th September 2026 at 3:00 PM IST
Scheduled at short notice due to the urgent nature of recent business developments and strategic growth initiatives
Dispensed with standard 2 working days' advance notice under SEBI Industry Standards Note Clause 19.1
Senior management including CFO Pardeep Kumar Khanna and Director Works Kushal Kumar Rana to attend

💡 Track the outcome of the conference call and subsequent exchange disclosures on September 11, 2026, to understand the exact nature of the strategic initiatives or business update.

IOLCP Announces ₹495 Cr Capex: 50% Ibuprofen Expansion, CDMO & Specialty Chemical Units

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 09 Sep 2026, 02:37 PM

IOL Chemicals has announced three strategic manufacturing initiatives with an aggregate capex of ₹495 crore, all funded via internal accruals (~27.5% of net worth). First, it is expanding its Ibuprofen capacity by 50% from 12,000 MTPA to 18,000 MTPA at a cost of ₹350 crore, slated for commissioning by December 2027. Second, it has set up a ₹110 crore formulations CDMO unit (1,500 million tablets/year) targeting Europe, which has received EU GMP approval from Hungary and is expected to commercialize in Q3 FY27. Third, it is investing ₹35 crore for a dedicated specialty chemicals tolling facility for a leading global chemical company, also targeted for Q3 FY27.

Ibuprofen capacity being expanded by 6,000 MTPA (50% increase) to 18,000 MTPA with ₹350 crore capex by Dec 2027
Current Ibuprofen capacity utilization stands at 95% on existing 12,000 MTPA base
New ₹110 crore formulations CDMO unit with 1,500 million tablets/year capacity received Hungary GMP compliance, commercializing in Q3 FY27
Dedicated specialty chemicals tolling facility with ₹35 crore capex signed with a leading global firm, commercializing in Q3 FY27
Total capital expenditure across all three projects is ₹495 crore, funded entirely via internal accruals

💡 Track commercialization progress of the formulations CDMO unit and specialty chemical plant in Q3 FY27, followed by the Ibuprofen unit execution by December 2027.

IOLCP Shareholders Approve All 3 AGM Resolutions at 39th Annual General Meeting

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 02 Sep 2026, 04:21 PM

IOL Chemicals and Pharmaceuticals Limited announced the voting results of its 39th Annual General Meeting held on September 2, 2026. All three ordinary resolutions were passed by shareholders, including the adoption of FY26 audited financial statements and the ratification of cost auditor remuneration for FY27 with near 100% approval. The re-appointment of director Mr. Kushal Kumar Rana was approved with 93.43% overall votes in favour, despite 91.34% of polled institutional votes casting against.

Adoption of FY26 audited standalone and consolidated financial statements passed with 100.00% votes in favour (19,70,97,082 votes)
Re-appointment of director Mr. Kushal Kumar Rana passed with 93.43% favourable votes, though 91.34% of institutional votes (1.30 cr votes) were against
Ratification of remuneration of the Cost Auditor for FY27 approved with 99.9987% votes in favour
Total voting participation stood at 67.15% to 67.17% of total voting capital across resolutions

💡 Track operational execution on capacity ramp-ups and next quarterly financial performance (Q2 FY27). No direct operational action arises from standard AGM voting results.

IOL Chemicals Concludes 39th AGM; All 3 Ordinary Resolutions Passed by Shareholders

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 02 Sep 2026, 03:06 PM

IOL Chemicals and Pharmaceuticals Limited conducted its 39th Annual General Meeting (AGM) on September 2, 2026, via Video Conferencing with 92 members in attendance. Shareholders approved all three ordinary resolutions with requisite majority, including the adoption of FY26 audited financial statements, re-appointment of director Mr. Kushal Kumar Rana retiring by rotation, and ratification of cost auditor remuneration for FY27. Both statutory and secretarial auditor reports were unqualified with no adverse remarks.

39th AGM successfully conducted on September 2, 2026, with 92 members attending via VC/OAVM
All 3 ordinary resolutions approved by members with requisite majority via remote e-voting and AGM e-voting
Adoption of FY26 Standalone and Consolidated Audited Financial Statements approved
Re-appointment of retiring director Mr. Kushal Kumar Rana and ratification of Cost Auditor remuneration for FY27 passed

💡 Track the upcoming Q2 FY27 operational results and progress on capacity utilization targets in regulated API export markets.

IOL Chemicals Schedules Institutional Investor Meeting for September 3, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Aug 2026, 04:20 PM

IOL Chemicals and Pharmaceuticals Limited has announced that its management will participate in an institutional investor meeting on September 3, 2026. The meeting will be an in-person, one-on-one interaction at the 'Market Marvel - Investing Beyond the Headlines' conference organized by Phillip Capital (India) Private Limited. The company confirmed that interactions will be limited to publicly available past performance data with no unpublished price-sensitive information shared.

Meeting scheduled for September 3, 2026 (Thursday)
Organized by Phillip Capital (India) Private Limited at the 'Market Marvel - Investing Beyond the Headlines' event
Format consists of in-person, one-on-one meetings with institutional investors and analysts
Company confirmed no unpublished price-sensitive information (UPSI) will be disclosed

💡 Track if the company uploads any fresh investor presentations or transcripts following the conference.

IOLCP Q1 FY27 Earnings Call: PAT Jumps 89.9% YoY to ₹64.5 Cr; FY27 Growth Guided at 15-20%

🟢 POSITIVE ⭐ 5/10

EARNINGS 📅 20 Aug 2026, 04:35 PM

IOL Chemicals and Pharmaceuticals reported a 37% YoY growth in Q1 FY27 revenue to ₹756 crore, driven by strong API diversification and higher capacity utilization. Operating EBITDA rose 60.7% YoY to ₹111 crore with margins expanding to 14.6% (up 220 bps YoY), while net profit surged 89.9% YoY to ₹64.5 crore. Non-Ibuprofen API revenue grew 67% YoY to account for 43% of pharma sales. For FY27, management guided for 15-20% revenue growth with EBITDA margins in the range of 14-15% and an export contribution of 25-30%.

Revenue from operations grew 37% YoY to ₹756 crore in Q1 FY27 compared to ₹551 crore in Q1 FY26
Net profit surged 89.9% YoY to ₹64.5 crore with PAT margin improving to 8.4% vs 6.1% in Q1 FY26
Non-Ibuprofen pharma revenue increased 67% YoY, contributing 43% of pharma sales vs 36% in Q1 FY26
FY27 guidance targets 15-20% revenue growth and 14-15% EBITDA margins with export share of 25-30%
Paracetamol capacity (10,800 MTPA) utilization stood at ~55%, targeted to reach ~70% by end of FY27

💡 Track the ramp-up in Paracetamol utilization toward the 70% target and the sustainability of EBITDA margins within the guided 14-15% range over upcoming quarters.

IOLCP Releases Audio Recording of Q1 FY2027 Analyst and Investor Call

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 13 Aug 2026, 05:24 PM

IOL Chemicals and Pharmaceuticals Limited (IOLCP) has released the audio recording of its Q1 FY2027 earnings call held on August 13, 2026. This is a standard regulatory disclosure following the announcement of quarterly financial results. Investors can use this recording to gain insights into management's strategy for achieving its 10-15% growth target and its progress in shifting toward regulated markets like the US and Europe. The company currently maintains a market-leading Ibuprofen capacity of 12,000 MTPA and is working to improve Paracetamol utilization from 55-56% to 65%.

Audio recording link for the Q1 FY2027 investor call held on August 13, 2026, has been made public.
Company is targeting a 10-15% growth rate by expanding its API portfolio and shifting to higher-margin regulated markets.
IOLCP maintains a significant global presence with an installed Ibuprofen capacity of 12,000 MTPA.
Management is focusing on increasing Paracetamol capacity utilization to 65% from the current 55-56% level.
Two products, Ibuprofen and Ethyl Acetate, continue to represent a high concentration of revenue at 72% as per FY24 data.

💡 Investors should listen to the recording specifically for management commentary on raw material price volatility in China and the timeline for scaling the new 'differentiated API pipeline' including Metformin and Clopidogrel.

89.9% PAT Growth in Q1 FY27; IOLCP Guides 15-20% Revenue Growth and Rs 250 Cr Capex

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 05:02 PM

IOLCP reported a strong Q1 FY27 with revenue growing 37.1% YoY to Rs 756.3 Cr and PAT surging 89.9% to Rs 64.5 Cr. The company is successfully diversifying its portfolio, with non-Ibuprofen APIs now contributing 37% of pharma sales compared to 18% in FY21. Management has provided a positive outlook for FY27, guiding for 15-20% revenue growth and EBITDA margins of 14-15%. To support this, a capex of Rs 200-250 Cr is planned, alongside the acquisition of 101 acres for a new manufacturing site.

Q1 FY27 PAT increased by 89.9% YoY to Rs 64.5 Cr, driven by margin expansion.
Revenue from operations grew 37.1% YoY to Rs 756.3 Cr for the quarter.
Non-Ibuprofen API share in the pharmaceutical segment reached 37% in FY26, up from 18% in FY21.
Management guided for a FY27 Capex of Rs 200-250 Cr, representing ~11-14% of current net worth.
Acquired 101 acres of land near Chandigarh-Bathinda Highway for future industrial expansion.

💡 Monitor the execution of the Rs 200-250 Cr capex and the timeline for regulatory approvals for the new 101-acre site. Watch for the company's ability to maintain the 14-15% EBITDA margin guidance amidst volatile raw material costs from China.

89.9% PAT Growth: IOLCP Reports Record ‡756.3 Cr Revenue in Q1 FY27

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 10 Aug 2026, 05:52 PM

IOLCP delivered a record-breaking Q1 FY27 with revenue growing 37.1% YoY to ‡756.3 Cr, significantly outpacing its historical quarterly run rate. Net profit (PAT) surged 89.9% YoY to ‡64.5 Cr, driven by a 43% growth in the Pharma segment and a massive 193% jump in Chemical segment EBIT. EBITDA margins expanded to 14.6% from 12.4% YoY, supported by higher capacity utilization and a better product mix. Notably, non-Ibuprofen products now contribute 43% of Pharma revenue, reducing concentration risk.

Revenue from operations reached a record ‡756.3 Cr, up 37.1% YoY and 22.1% QoQ.
Net Profit (PAT) grew 89.9% YoY to ‡64.5 Cr, accounting for approximately 47% of the total TTM PAT.
Pharma segment revenue grew 43% YoY to ‡469.5 Cr, with EBIT rising 72% YoY.
Paracetamol capacity utilization improved to 65%, meeting the company's previously stated target.
Export contribution increased to 28.5% of total revenue, up from 24.4% in the same quarter last year.

💡 Monitor the sustainability of the 14.6% EBITDA margin and the volume ramp-up in the Chinese market following the recent NMPA approval for Clopidogrel API.

90% PAT Growth: IOLCP Reports Strong Q1 FY27 with ₹756 Cr Revenue

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 10 Aug 2026, 02:18 PM

IOLCP reported a robust start to FY27, with consolidated revenue growing 37.1% YoY to ₹756.26 Cr. Net profit surged 89.9% YoY to ₹64.48 Cr, significantly exceeding the quarterly average of the previous year. The growth was primarily driven by the Pharmaceutical segment, which saw a 42.6% YoY revenue increase, while the Chemical segment's profitability (PBIT) nearly tripled to ₹17.32 Cr.

Revenue from operations increased 37.1% YoY to ₹756.26 Cr from ₹551.69 Cr.
Net profit for the quarter rose 89.9% YoY to ₹64.48 Cr compared to ₹33.96 Cr in Q1 FY26.
Pharmaceutical segment revenue grew 42.6% YoY to ₹469.49 Cr, now contributing 56% of gross segment revenue.
Chemical segment PBIT improved significantly to ₹17.32 Cr from ₹5.91 Cr in the year-ago period.
Quarterly EPS stood at ₹2.20, which is approximately 47% of the total FY26 EPS of ₹4.69.

💡 Investors should monitor the sustainability of the Pharmaceutical segment's growth and whether the Chemical segment can maintain its improved margins despite raw material volatility. Watch for management commentary on Paracetamol capacity utilization reaching the 65% target.

View All IOLCP Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In Q2 FY26, total revenue from operations reached INR 567.5 Cr, reflecting a 7.9% YoY growth. Historically, in FY24, the Pharma segment remained stable with a marginal 0.3% increase, while the Chemical segment saw a 9% decline due to pricing pressures. The company is currently targeting a 10-15% annual revenue growth across segments.

Geographic Revenue Split

The company is strategically shifting from domestic to regulated markets (Europe and US) to improve price realization. It aims to increase its export revenue share to approximately 40% of total sales, supported by 15 DMFs and 20 CEPs filed for regulated markets.

Profitability Margins

Profitability showed significant YoY improvement in Q2 FY26 with PAT margins rising to 5.2% from 3.6% (INR 30 Cr, up 56.7% YoY). However, margins saw a temporary sequential dip due to elevated fuel costs (Punjab floods). FY24 PAT margin stood at 6.31% (INR 135.42 Cr) but moderated to 4.8% (INR 101 Cr) in FY25.

EBITDA Margin

EBITDA for Q2 FY26 was INR 64 Cr, a 33.3% YoY increase, with margins expanding by 212 basis points to 11.1%. The company targets an EBITDA margin of 13-14% in the near term, expecting a 1-2% annual improvement through better product mix and operational leverage.

Capital Expenditure

IOLCP plans to fund its entire capex for the next three years through internal accruals. Recent investments are focused on automation, infrastructure upgrades, and scaling the differentiated API pipeline to support a 10-15% growth trajectory.

Credit Rating & Borrowing

The company maintains a strong credit profile with CARE A+ (Stable) for long-term and CARE A1+ for short-term facilities. Overall gearing is low at 0.24x as of March 31, 2025, with an interest coverage ratio of 14.27x.

⚙️ Operational Drivers

Raw Materials

Key raw materials include Acetic Acid (primary for Ethyl Acetate), Iso-Butyl Benzene (IBB), and various chemical intermediates for APIs like Metformin and Paracetamol. Raw materials are a major cost driver, with Ethyl Acetate and Ibuprofen accounting for 72% of FY24 revenue.

Import Sources

The company procures the majority of its raw materials for the chemical segment from China. API raw materials are primarily sourced from the domestic Indian market.

Capacity Expansion

Total blended manufacturing capacity reached 1,80,222 MTPA as of March 31, 2025, up from 1,72,962 MTPA in FY24. Paracetamol capacity utilization is currently 55-56%, with a target to reach 65% by next year.

Raw Material Costs

Raw material costs are volatile; for instance, Ethyl Acetate margins are highly sensitive to Acetic Acid price fluctuations. The company passes on cost increases to customers with a lag of approximately two months due to inventory processing cycles.

Manufacturing Efficiency

Efficiency is driven by integrated operations where chemical segment products serve as intermediates for the API segment, reducing overall cost structures and improving operating leverage.

📈 Strategic Growth

Expected Growth Rate

10-15%

Growth Strategy

Growth will be achieved by shifting the customer base from domestic to regulated markets (Europe/US) to capture higher margins, increasing Paracetamol capacity utilization to 65%, and expanding the API portfolio (Metformin, Clopidogrel, Pantoprazole). The company is also securing clearances for new land for future industrial expansion.

Products & Services

Major products include Ibuprofen (36% of sales), Ethyl Acetate (36% of sales), Metformin, Paracetamol, Clopidogrel, Fenofibrate, Pantoprazole, Acetyl Chloride, and Iso-Butyl Benzene.

Brand Portfolio

IOL Chemicals and Pharmaceuticals Limited (IOLCP).

New Products/Services

The company is scaling its 'differentiated API pipeline' and has recently introduced Metformin, Clopidogrel, and Fenofibrate to reduce product concentration risk.

Market Expansion

Targeting regulated markets with 18 approved CEPs and 15 DMFs. The company is specifically looking to grow its presence in the US and Europe to achieve a 40% export revenue share.

Market Share & Ranking

IOLCP is a well-established market leader in Ibuprofen globally, with an installed capacity of 12,000 MTPA.

🌍 External Factors

Industry Trends

The industry is shifting toward high-quality, regulated market manufacturing. IOLCP is positioning itself by moving away from the domestic-heavy mix to a 40% export-oriented model to capture stable demand and better pricing.

Competitive Landscape

The company faces competition from domestic and Chinese manufacturers in the API and Ethyl Acetate markets, leading to selling price pressure as seen in Q1 FY25.

Competitive Moat

The moat is built on backward integration and cost leadership in Ibuprofen. By manufacturing its own key starting materials (KSMs) like IBB, IOLCP maintains a favorable cost structure that is difficult for non-integrated competitors to match.

Macro Economic Sensitivity

The business is sensitive to global pharmaceutical demand and industrial chemical cycles. Inflation in fuel and raw material costs directly impacts the 11.1% EBITDA margin.

Consumer Behavior

Stable and growing global demand for essential APIs like Ibuprofen and Paracetamol supports long-term volume recovery.

Geopolitical Risks

Heavy reliance on China for raw materials (Acetic Acid) exposes the company to trade disruptions and geopolitical tensions between India and China.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to USFDA standards (Ibuprofen facility approved in FY20). Notably, IOLCP's products are not covered under the Drug Price Control Order (DPCO), allowing for more flexible pricing.

Environmental Compliance

The company is in the process of securing environmental clearances for new land. It has received approvals from pollution control boards and focuses on minimizing adverse impacts on health and safety.

Taxation Policy Impact

The effective tax rate resulted in a PAT of INR 30 Cr from a PBT level in Q2 FY26, reflecting standard corporate tax applications.

Legal Contingencies

As of March 31, 2025, no significant or material orders were passed by regulators, courts, or tribunals impacting the company's status as a going concern. No proceedings are admitted under the Insolvency and Bankruptcy Code.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the volatility of raw material prices from China, which can impact margins by 1-2% annually. Regulatory delays in new product approvals could also impact the 10-15% growth target.